Tumor invasion is negatively correlated with SSTR2 level but is not associated with other SSTR subtypes. Patients with invasive tumors have a poorer response to SSA therapy, which may be due to the low level of SSTR2 expression. Therefore, SSTR2 could be considered as a routine investigative marker for aiding management of postoperative residual tumors.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: